- Home
- MOB vs RNXT Comparison
MOB vs RNXT Comparison
Compare MOB & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MOB | RNXT |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.7M | 79.4M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MOB | RNXT |
|---|---|---|
| Price | $4.05 | $1.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $11.00 | $7.13 |
| AVG Volume (30 Days) | 124.2K | ★ 651.1K |
| Earning Date | 08-13-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,123,000.00 |
| Revenue This Year | $134.74 | $244.84 |
| Revenue Next Year | $150.00 | $195.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2511.63 |
| 52 Week Low | $3.90 | $0.70 |
| 52 Week High | $10.75 | $2.59 |
Technical Indicators
Market Signals| Indicator | MOB | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 34.03 | 35.68 |
| Support Level | N/A | $0.83 |
| Resistance Level | $5.54 | $1.51 |
| Average True Range (ATR) | 0.25 | 0.11 |
| MACD | -0.06 | -0.05 |
| Stochastic Oscillator | 5.66 | 5.66 |
Price Performance
Historical ComparisonAbout MOB Mobilicom Limited
Mobilicom Ltd is a provider of cybersecurity and smart solutions for drones, robotics & autonomous platforms. As a high-tech company, it designs, develops, and delivers smart solutions targeting global drone, robotics, and autonomous system manufacturers. Its products include OS3 Platform Software, ICE Cybersecurity Software, MCU Mesh Networking, SkyHopper Datalinks, Mobile Ground Control Stations and System Engineering Services.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.